Favorable immune checkpoint inhibitor outcome of patients with melanoma and NSCLC harboring FAT1 mutations

Immune checkpoint inhibitors (ICIs) are most commonly used for melanoma and non-small cell lung cancer (NSCLC) patients. FAT atypical cadherin 1 (FAT1), which frequently mutates in melanoma and NSCLC. In this study, we aim to investigate the association of FAT1 mutations with ICI response and outcom...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Wenjing, Tang, Yunfeng, Guo, Yuxian, Kong, Yujia, Shi, Fuyan, Sheng, Chao, Wang, Suzhen, Wang, Qinghua
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9226130/
https://www.ncbi.nlm.nih.gov/pubmed/35739249
http://dx.doi.org/10.1038/s41698-022-00292-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9226130/
https://www.ncbi.nlm.nih.gov/pubmed/35739249
http://dx.doi.org/10.1038/s41698-022-00292-6

Ejemplares similares